Press and Media

Home / Meetings / Press and Media
Thank you for your coverage of the AANEM Annual Meeting. Please join us at the 2025 AANEM Annual Meeting, being held Oct.29-Nov. 1 in San Francisco, California. Journalists covering the annual meeting and posting stories on social media channels are encouraged to use the official meeting hashtag #AANEMinSanFran.
Please review the Abstract Embargo Policy. For questions regarding AANEM Annual Meeting policies, please email communications@aanem.org.

View the latest AANEM Achievement Award winners, the American Neuromuscular Foundation (ANF) Abstract Award winners, and the latest AANEM news articles on News Express.

Questions? Check out the frequently asked questions below or contact communications@aanem.org. 

Frequently Asked Questions

Q: When will be content of abstracts be viewable, as opposed to just the titles?
A: The abstract content will be available at the annual meeting during the Poster Hall hours. We do not provide abstract presenter information or slides ahead of time. All available information can be found in the AANEM Abstract Guide online when it becomes available.

Q: How do I reach out to abstract or session presenters for an interview?
A: We do not offer member contact information. To connect with abstract or session presenters, review the AANEM Annual Meeting Program when available. Find the topics of interest and connect with the presenter after their lecture or during their abstract poster session time. Currently there is no interview option for virtual attendees.

Q: When can I share information?
A: The embargo on the abstracts themselves is lifted when they have been published in Muscle & Nerve and online in the AANEM Abstract Guide. However, the additional information beyond what is in the abstract itself is still embargoed. 

AANEM requires information that goes beyond that which is contained within the abstract, e.g., the release of data not included in the abstract, discussion of the abstract done as part of a scientific presentation, etc. to be embargoed until the start of the annual meeting. Please see the Abstract Embargo Policy.

Q: Will the Abstract Award Reception feature the best posters? 
A: The Abstract Award Reception is a social hour in honor of the abstract award winners where all authors, including award winners, will be available to discuss research. 

Q: Original research is ONLY presented as posters, correct?
A: Yes - the research is presented in the Poster Hall via abstract posters.

Remembering Peter J. Dyck, MD

Sep 3, 2025, 13:29 by Maggie Schmidt (Admin)

 

AANEM remembers Peter J. Dyck, MD, a remarkable neurologist, educator, and researcher who passed away July 26, 2025, at his home in Rochester, Minnesota. Dr. Dyck became an Honorary Member of AANEM in 2001 in recognition of his extraordinary contributions to the understanding and treatment of peripheral nerve disorders. He remained an active part of the AANEM community, serving on the Muscle & Nerve Editorial Board and presenting research at the AANEM Annual Meetings.


Dr. Dyck studied medicine at the University of Toronto, graduating in 1955 before moving to Rochester, Minnesota in 1959 to train in neurology at the Mayo Clinic. He would remain there for the rest of his distinguished 7-decade career, retiring in 2024 as the longest-serving physician in Mayo Clinic history.

Dr. Dyck’s scientific legacy is unparalleled in the field of NM and EDX medicine. He authored more than 460 peer-reviewed publications and five textbooks. He and Edward Lambert, MD, PhD, were the first to show that nerve conduction studies could be used to detect and predict Charcot-Marie-Tooth disease. He reintroduced the use of nerve biopsies and helped develop clinical neuropathy scoring systems and computerized sensory testing.

In 1975, Dr. Dyck published the first major series describing chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), identifying it as a distinct condition and leading early clinical trials showing that prednisone, IVIg, and plasma exchange were effective treatments. He later conducted landmark studies on diabetic and monoclonal gammopathy-related neuropathies and led international trials of novel treatments including nerve growth factor and alpha-lipoic acid.

Dr. Dyck trained more than 150 fellows and served as president of the American Neurological Association and the Peripheral Nerve Association. He co-founded the Peripheral Nerve Society, helping shape the future of NM research and care. AANEM is honored to have counted Dr. Dyck among its members and will remember him with great respect and gratitude.